{"abstract":"The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this notice to BravoVax Co., Ltd located in Wuhan, China.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2017/11/29/2017-25744.html","cfr_references":[],"citation":"82 FR 56621","comment_url":null,"comments_close_on":"2017-12-14","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before December 14, 2017 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2017-25744","effective_on":null,"end_page":56622,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2017/11/29/2017-25744.xml","html_url":"https://www.federalregister.gov/documents/2017/11/29/2017-25744/prospective-grant-of-an-exclusive-patent-license-concatenated-l2-peptide-based-human-papillomavirus","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2017-25744?publication_date=2017-11-29","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2017-11-29/2017-25744/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":152,"last_updated":"2026-07-28 04:15:03 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2017-11-29/pdf/2017-25744.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2017-25744.pdf?1511876731","publication_date":"2017-11-29","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2017/11/29/2017-25744.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-02-28T20:14:53Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":56621,"subtype":null,"title":"Prospective Grant of an Exclusive Patent License: Concatenated L2 Peptide Based Human Papillomavirus Vaccines","toc_doc":"Concatenated L2 Peptide Based Human Papillomavirus Vaccines","toc_subject":"Prospective Grants of Exclusive Patent Licenses:","topics":[],"type":"Notice","volume":82}